linjc16/ctgov huggingface dataset:
Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel

Study Overview
=================
Brief Summary
-----------------
A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1 month. VerifyNow® and Global thrombosis test were performed at day 2 and 1 month after administration of study drugs. The investigators compared aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU), occlusion time (OT) which reflects shear stress-induced thrombotic activity, and lysis time (LT) which showed endogenous lytic activity between the two strategies at both time points.

Official Title
-----------------
Comparison of Shear Stress-induced Thrombotic and Thrombolytic Effect d Thrombolytic Effect Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel in Patients With Acute Coronary Syndrome

Conditions
-----------------
Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were diagnosed with acute coronary syndrome and underwent percutaneous coronary intervention Exclusion Criteria: Patients administered with glycoprotein IIb/IIIa inhibitiors Patients with atrial fibrillation Patients with high risk of bleeding at the physician's discretion Patients with renal impairment (estimated GFR <30ml/min)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ticagrelor<br>ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid) | |
| Clopidogrel + very low dose rivaroxaban<br>ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occlusion time | Global thrombosis test | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lysis time | Global thrombosis test | 1 month | 
| Occlusion time | Global thrombosis test | Day 2 | 
| Lysis time | Global thrombosis test | Day 2 | 
| P2Y12 reaction unit | VerifyNow test | Day 2 and 1 month | 
| Aspirin reaction unit | VerifyNow test | Day 2 and 1 month |
Skin Irritation Test of Ten Products

Study Overview
=================
Brief Summary
-----------------
Evaluation of cutaneous tolerance of ten products by primary irritant patch test

Detailed Description
-----------------
The purpose of this clinical study was the evaluation of skin irritation potential of ten products after a single application under occlusive patch on human skin.

Official Title
-----------------
Skin Irritation Test of Ten Products

Conditions
-----------------
Dermatitic Reaction of Face

Intervention / Treatment
-----------------
* Other: ten products (S01 S10) and two blank (BK1, BK2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 to 70 years old, healthy male and female (sex ratio 1:1) No acute or chronic diseases including skin diseases. No current medications. Exclusion Criteria: Pregnancy or breast feeding. Abnormal blood test result/results (evaluation criteria: WBC, AST, ALT, and Creatinine) Back skin with moles, acne, tattoo, scars, red spots, burns, etc. Current dermatology medication which might affect skin condition evaluation. Current irritated reaction on test site. Participating in other clinical trial(s) within 7 days.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Single arm<br> | Other: ten products (S01 S10) and two blank (BK1, BK2)<br>* S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety/Adverse Event Outcome Measure | Number of participants with Serous and Non-Serous Adverse Event | Up to 48 hours | 
| Total Number of Positive Responses Across All Participants | Change from baseline of test products by using ICDRG (International Contact Dermatitis Research Group) grading | Reading results at 30 minutes, 24 hours and 48 hours after the removal of the test products. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
skin, skin health, allergen
Characterization of Phenotypes of Occupational Asthma

Study Overview
=================
Brief Summary
-----------------
The general objective of this multicenter, international study is to perform a multivariate descriptive analysis of a large population of well-defined subjects with sensitizer-induced OA ascertained by a positive SIC result in order to provide more information on the characteristics of this condition.

Official Title
-----------------
Characterization of Phenotypes of Occupational Asthma: Descriptive Study

Conditions
-----------------
Occupational Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Patient Patient who performed a specific inhalation test with a positive result between January 2006 and December 2015.- Subject giving their consent for their participation Patient agreeing to use his data for research purposes Exclusion Criteria: Patient objecting to the use of his data for research purposes Subjects under safeguard of justice Subject under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study to perform a multi-varied descriptive analysis of a cohort of patients with occupational asthma confirmed by a specific inhalation test |  | The period from from January 1st, 2006 to December 31st, 2015 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, occupational asthma
Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication

Study Overview
=================
Brief Summary
-----------------
Efffect of a single dose oral intake of sildenafil Or placebo on the walking capacity on treadmill of PAD patients with claudication

Detailed Description
-----------------
Sildenafil 100mg or Placebo Oral intake 2 hours before the treadmill test Safety and security control throughout the period of drug efficacy (approx 4 hours) Evaluation of maximal walking distance for a constant load treadmill test (3.2 kml/h 10% slope)

Official Title
-----------------
Etude préliminaire Sur l'efficacité Aigue du Sildenafil Sur le Temps de Marche Chez Les Patients Atteints d'AOMI de Stade II présentant Une Claudication artérielle

Conditions
-----------------
Peripheral Arterial Occlusive Disease

Intervention / Treatment
-----------------
* Drug: Sildenafil 100mg single oral dose
* Drug: Placebo, Oral intake single dose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with peripheral arterial desease stade II Patient with vascular claudication for at least 3 months Patient able to perform a treadmill walking test with time to walk < 5min Exclusion Criteria: Patient suffering from ischemia Previous angina or myocardial Patient treated with nitrates drugs Patient with severe renal insufficiency Patient with severe hepatic insufficiency Patient with hypotension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sildenafil<br>Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test. | Drug: Sildenafil 100mg single oral dose<br>* Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)<br>* Other names: Viagra verventi;|
| Placebo Comparator: Placebo<br>Single placebo intake approximately 2 hours before the treadmill test. | Drug: Placebo, Oral intake single dose<br>* Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)<br>* Other names: Sugar pills manufactured to mimick Sildenafil 100 mg;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Walking duration on treadmill | Treadmill test with consttant load procedure 3.2 km/h H 10% slope up to 15 minutes followed by incremental load according tpo the Bruce protocole thereafter. | 2 hours after treatment intake |
Nutritional State and Intake Nutrients Assessment in Ulcerative Colitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the reason patients are deficient in nutrients intake such as antioxidants vitamins.

Official Title
-----------------
Nutritional State in Ulcerative Colitis Patients

Conditions
-----------------
Ulcerative Colitis in Remission

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Ulcerative Colitis in remission Age > 18 yo Exclusion Criteria: Patients with Ulcerative Colitis in activity Those patients with food intake trouble Those patients with bowel resected

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nutritional state, nutrients intake, ulcerative colitis
Common Allergens in Skin Tests for Adult Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
To analyze the common allergens revealed by skin tests in adult atopic dermatitis patients.

Detailed Description
-----------------
The allergens involved in atopic patients are widely existed in our environment. Traditionally, we use serum specific IgE, skin prick test or intradermal test to verify the possible causative allergens in patients with atopic dermatitis. This study will evaluate the correlation between serum specific IgE, skin prick test, intradermal test, and patch test for common allergens in adult patients with atopic dermatitis.

Official Title
-----------------
Common Allergens in Skin Tests for Adult Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with atopic dermatitis (according to Hanifin and Rajka criteria) age older than 16 years old Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atopic dermatitis, skin test
Filgrastim for the Promotion of Collateral Growth in Patients With CAD

Study Overview
=================
Brief Summary
-----------------
The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.

Detailed Description
-----------------
The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.

Official Title
-----------------
Subcutaneous Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Filgrastim (rG-CSF)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old 1- to 3-vessel coronary artery disease (CAD) Stable angina pectoris At least 1 stenotic lesion suitable for PCI No Q-wave myocardial infarction in the area undergoing CFI measurement Written informed consent to participate in the study Exclusion Criteria: Patients admitted as emergencies Acute myocardial infarction Unstable CAD CAD treated best by CABG Patients with overt neoplastic disease Patients with diabetic retinopathy Liver or kidney disease Pre-menopausal women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Filgrastim (rG-CSF)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collateral flow index (CFI) at 2 weeks follow-up compared to baseline CFI |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute myocardial perfusion during hyperemia by contrast echocardiography (MCE) at baseline, at 2 weeks and at 6 month follow-up |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAD, G-CSF, Collaterals, CFI, perfusion
hCG Supplementation in Frozen-Thawed Embryo Transfer Cycle

Study Overview
=================
Brief Summary
-----------------
The implantation rate after frozen-thawed embryo transfer cycles depends mostly on the receptivity of the endometrium and the embryo quality.The effects of human chorionic gonadotropins (hCG) on the endometrium have been investigated for several years. hCG was shown to up-regulate gene expression during the differentiation of human endometrial stromal cells into decidua. The aim of our study was to assess the benefit of hCG supplementation throughout the secretory phase of artificial frozen-thawed embryo transfer cycles.

Official Title
-----------------
The Benefit of Human Chorionic Gonadotropin (hCG) Supplementation Throughout the Secretory Phase of Frozen-Thawed Embryo Transfer Cycles

Conditions
-----------------
Fertility Agents, Female

Intervention / Treatment
-----------------
* Drug: s.c. human chorionic gonadotropin (Ovitrelle)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all women on frozen-thawed embryo-transfer cycle Exclusion Criteria: any allergy to injection of human chorionic gonadotropin before

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>receiving hCG injection | Drug: s.c. human chorionic gonadotropin (Ovitrelle)<br>* S.C. Ovitrelle 250 mcg once<br>|
| Placebo Comparator: B<br> | Drug: s.c. human chorionic gonadotropin (Ovitrelle)<br>* S.C. Ovitrelle 250 mcg once<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| implantation rate |  | 4 weeks | 
| pregnancy rate |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
In-Vitro Fertilization, human chorionic gonadotropin, frozen-thawed embryo transfer, implantation rate
Medical Nutrition Therapy Intervention Program for Women With Gestational Diabetes--a Prospective Study

Study Overview
=================
Brief Summary
-----------------
Gestational diabetes mellitus (GDM) is one of the most frequent complications of pregnancy, that affect between 1 to 14% of population around the world. The overall purpose of this study is to determine the efficacy of individualized medical nutrition therapy (MNT) intervention to reduce and control the development of GDM.

Detailed Description
-----------------
The number of women with gestational diabetes mellitus had been increasing. Maternal GDM has a great impact on both the health of the mothers and the offspring. Antenatal lifestyle interventions, in particular dietary intervention appear to be feasible to improve maternal GDM and weight gain. To the best of our knowledge, there has been no such trial examining the feasibility of MNT intervention in pregnant women in Hu'nan province. The aim of this study is to evaluate the efficacy of individualized MNT intervention to reduce and control the development of GDM. This is a prospective study, 500 patients who meet inclusion and exclusion criteria will be included. The changes of glucose and weight will be evaluated every two weeks.

Official Title
-----------------
Individualized Medical Nutrition Therapy Intervention Program for Women With Gestational Diabetes

Conditions
-----------------
Diabetes, Gestational

Intervention / Treatment
-----------------
* Behavioral: Individualized medical nutrition therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with gestational diabetes Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Individualized medical nutrition therapy<br>A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual | Behavioral: Individualized medical nutrition therapy<br>* The intervention group involves dietary and exercise advice and monitoring.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intravenous glucose | Investigators will measure the participants' intravenous glucose every two weeks.From date of randomization until the date of parturition,assessed up to 10 months. | every two weeks, from date of randomization until the date of parturition, assessed up to 10 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Gestational, Nutrition Therapy